Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Dentoxol® Mouthrinse for Oral Mucositis Secondary to Radiation Therapy for Head and Neck Cancer

NCT02885376 is registered in ClinicalTrials.gov with Ingalfarma SpA as lead sponsor.

NCT NCT02885376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02885376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Dentoxol® Mouthrinse for Oral Mucositis Secondary to Radiation Therapy for Head and Neck Cancer
Lead sponsor
Ingalfarma SpA
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
August 31, 2018
Enrollment
108 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

oral mucositis